More meeting highlights from ASCO in cancer prevention, diagnosis, and treatment--in case your patient asks.
Slide Show: Get top-line results of 10 new studies on the most common non-skin cancer among US men.
Take this quick quiz to test your knowledge of this deadly disease.
Find ASCO meeting highlights here, with an emphasis on primary care’s role in cancer management.
If the answer to the question "Does PSA screening save lives?" is "yes," where do we go from there?
A new review on the topic in the NEJM covers everything you need to know. We preview with a short Q&A for primary care.
A range of options for metastatic castration resistant prostate cancer offer benefits, but impact on survival and sequencing guidance are less than optimal.
As new teaching replaces old, it seems testosterone replacement may have gone from bad to good and even very good. Here’s how.
African American and white men in racially integrated communities with comparable incomes have far fewer differences in behaviors that contribute to poor health, this study showed.
New guidelines recommend that testosterone replacement therapy be restricted to men who have stable disease, only after a discussion of the potential risks and benefits.